Pharvaris
PHVS
21 hedge funds and large institutions have $174M invested in Pharvaris in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 4 closing their positions.
1.45% more ownership
Funds ownership: 64.26% → 65.71% (+1.4%)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
16% less funds holding
Funds holding: 25 → 21 (-4)
27% less capital invested
Capital invested by funds: $240M → $174M (-$65.8M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$4.04M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$1.25M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$237K |
| 4 |
Morgan Stanley
New York
|
+$95.1K |
| 5 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$7.92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$498K |
| 2 |
Walleye Capital
New York
|
-$364K |
| 3 |
VP
venBio Partners
San Francisco,
California
|
-$160K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$146K |
| 5 |
QT
Quantamental Technologies
White Plains,
New York
|
-$145K |
PHVS Hedge Fund Activity: Q1 2023 in Review
21 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Pharvaris (PHVS) for Q1 2023, worth a combined $174M — down 27% from $240M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of PHVS and 0 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Silverarc Capital Management, adding an estimated $4.04M. The largest seller was Sio Capital Management, cutting an estimated $498K.
- 21 institutional investors held Pharvaris (PHVS) as of Q1 2023, down from 25 in Q4 2022.
- Funds reported $174M of Pharvaris stock for Q1 2023, down 27% quarter-over-quarter.
- 0 funds opened new Pharvaris positions in Q1 2023 and 4 closed out, a net change of -4 holders.
- The largest Pharvaris buyer in Q1 2023 was Silverarc Capital Management, an estimated $4.04M added.
- The largest Pharvaris seller in Q1 2023 was Sio Capital Management, an estimated $498K sold.
Based on aggregated 13F filings for Q1 2023.